ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Claritas Pharmaceuticals Inc

Claritas Pharmaceuticals Inc (CLAS)

0,025
0,00
( 0,00% )
Aktualisiert: 01:00:00

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Current Price
0,025
Gebot
0,025
Fragen
0,035
Volumen
-
0,00 Tagesbereich 0,00
0,025 52-Wochen-Bereich 0,025
Handelsende
0,025
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
-
Durchschnittliches Volumen (3 Mio.)
-
Finanzvolumen
-
VWAP
-

CLAS Neueste Nachrichten

Claritas Announces Approval from OTC to Up-List to OTCQB

SAN FRANCISCO, CA and TORONTO, ON, April 07, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the "Company" or "Claritas") is pleased to...

Claritas Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107

SAN FRANCISCO, CA and TORONTO, ON, April 05, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the "Company" or "Claritas") today announced...

Claritas Announces Receipt of Comments from Australian Ethics Committee Regarding the Company’s Phase 1 Clinical Study of R-107 and Closing of Financing

SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has...

Claritas Anticipates Response from Australian Ethics Committee by February 18, 2022

SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that the...

Claritas Announces Revised, Improved Terms for Initial Tranche of Financing with Alumina Partners

SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas”) today announced revised...

Claritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe Burns

SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas") today announced that it has...

Claritas Announces New Registered and Records Office Address, Confirms its Management and Directors and Announces Terms of Initial Tranche of Equity Financing with Alumina Partners

SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced the Company’s...

Claritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.

SAN FRANCISCO, CA and TORONTO, ON, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") is pleased to announce it has...

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

SAN FRANCISCO, CA and TORONTO, ON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today outlined the Company’s...

Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

SAN FRANCISCO, CA, and TORONTO, ON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it will...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1000.0250.0250.02500CS
4000.0250.0250.02500CS
12000.0250.0250.02500CS
26000.0250.0250.02500CS
52000.0250.0250.02500CS
156-0.15-85.71428571430.1750.190.025105770.09086787CS
260-0.025-500.050.750.021352380.05654276CS

CLAS - Frequently Asked Questions (FAQ)

What is the current Claritas Pharmaceuticals share price?
The current share price of Claritas Pharmaceuticals is $ 0,025
What is the 1 year trading range for Claritas Pharmaceuticals share price?
Claritas Pharmaceuticals has traded in the range of $ 0,025 to $ 0,025 during the past year
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
RCTRochester Resources Ltd
$ 0,05
(233,33%)
233,5k
ETUE2gold Inc
$ 0,01
(100,00%)
358,31k
AKH.HAlaska Hydro Corporation
$ 0,03
(100,00%)
4,03k
TVITVI Pacific Inc
$ 0,01
(100,00%)
6,59k
MVYMoovly Media Inc
$ 0,01
(100,00%)
52,63k
MPTH.HMapath Capital Corp
$ 0,015
(-57,14%)
1.000
TMS.HTargeted Microwave Solutions Inc
$ 0,005
(-50,00%)
1.000
KLMKermode Resources Ltd
$ 0,005
(-50,00%)
100k
ICRSIcarus Capital Corp
$ 0,015
(-50,00%)
10k
CHSComprehensive Healthcare Systems Inc
$ 0,01
(-33,33%)
915k
NDANeptune Digital Assets Corp
$ 1,93
(-11,47%)
2,11M
AFMAlphamin Resources Corp
$ 0,96
(-10,28%)
2,02M
TDGTDG Gold Corp
$ 0,455
(1,11%)
1,84M
AAZAzincourt Energy Corp
$ 0,02
(33,33%)
1,83M
SCLTSearchlight Resources Inc
$ 0,015
(50,00%)
1,66M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock